Lung cancer biology varies between never-smokers and smokers.1,3,6,7 Lung adenocarcinomas in never-smoker patients exhibit a higher frequency of EGFR, PIK3CA, and ERBB2 mutations.1,6EGFR mutations are notably more common, at variance with KRAS mutations, which are associated with tobacco exposure.2-4 Moreover, LCINS are more likely to harbor actionable variants, including not only EGFR mutations but also ALK translocation, impacting patients’ clinical management.1,3. Here, ERBB2 is linked to lung adenocarcinoma.